Avian influenza A (H5N1) virus in dairy cattle: origin, evolution, and cross-species transmission.

Autor:	Mostafa A; Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, Texas, USA.; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt., Naguib MM; Department of Infection Biology and Microbiomes, University of Liverpool, Liverpool, United Kingdom.; Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden., Nogales A; Center for Animal Health Research, CISA-INIA-CSIC, Madrid, Spain., Barre RS; Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, Texas, USA., Stewart JP; Department of Infection Biology and Microbiomes, University of Liverpool, Liverpool, United Kingdom., García-Sastre A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; The Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Martinez-Sobrido L; Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Jazyk:	angličtina
Zdroj:	MBio [mBio] 2024 Dec 11; Vol. 15 (12), pp. e0254224. Date of Electronic Publication: 2024 Nov 13.
DOI:	10.1128/mbio.02542-24
Abstrakt:	Since the emergence of highly pathogenic avian influenza virus (HPAIV) H5N1 of clade 2.3.4.4b as a novel reassortant virus from subtype H5N8, the virus has led to a massive number of outbreaks worldwide in wild and domestic birds. Compared to the parental HPAIV H5N8 clade 2.3.4.4b, the novel reassortant HPAIV H5N1 displayed an increased ability to escape species barriers and infect multiple mammalian species, including humans. The virus host range has been recently expanded to include ruminants, particularly dairy cattle in the United States, where cattle-to-cattle transmission was reported. As with the avian 2.3.4.4.b H5N1 viruses, the cattle-infecting virus was found to transmit from cattle to other contact animals including cats, raccoons, rodents, opossums, and poultry. Although replication of the virus in cows appears to be mainly confined to the mammary tissue, with high levels of viral loads detected in milk, infected cats and poultry showed severe respiratory disease, neurologic signs, and eventually died. Furthermore, several human infections with HPAIV H5N1 have also been reported in dairy farm workers and were attributed to exposures to infected dairy cattle. This is believed to represent the first mammalian-to-human transmission report of the HPAIV H5N1. Fortunately, infection in humans and cows, as opposed to other animals, appears to be mild in most cases. Nevertheless, the H5N1 bovine outbreak represents the largest outbreak of the H5N1 in a domestic mammal close to humans, increasing the risk that this already mammalian adapted H5N1 further adapts to human-to-human transmission and starts a pandemic. Herein, we discuss the epidemiology, evolution, pathogenesis, and potential impact of the recently identified HPAIV H5N1 clade 2.3.4.4b in dairy cattle in the United States. Eventually, interdisciplinary cooperation under a One Health framework is required to be able to control this ongoing HPAIV H5N1 outbreak to stop it before further expansion of its host range and geographical distribution. Competing Interests: The A.G.-S. laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories, and Merck. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer, and Prosetta. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, Astrazeneca, and Novavax. A.G.-S. is an inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. All other authors declare no commercial or financial conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu